Reduction of cellular cisplatin resistance by hyperthermia - A review

International Journal of Hyperthermia

Volumn 13, Issue 5, 1997, Pages 439-457

  Hettinga, J V E ^a   Konings, A W T ^a   Kampinga, H H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

CDDP resistance; Mechanism of sensitization; Reversal of resistance; Review; Thermochemosensitization

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ANIMAL CELL; CANCER; CYTOTOXICITY; DNA ADDUCT; DRUG ACCUMULATION; HEATING; HYPERTHERMIC THERAPY; MEDICAL LITERATURE; NONHUMAN; PLEIOTROPY; REVIEW; TEMPERATURE;

EID: 0030781017     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.3109/02656739709023545     Document Type: Review

References (94)

1. ALEXANDER, H. R., and FRAKER, D. L., 1995, Continuous hyperthermic peritoneal perfusion with cisplatin in the treatment of peritoneal carcinomatosis. Regional Cancer Treatments, 8, 2-7.
2. ANDREWS, P. A., and HOWELL, S, B., 1990, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43.
3. ANDREWS, P. A., MANN, S. C., VELURY, S., and HOWELL, S. B., 1988, Cisplatin uptake mediated cisplatin-resistance in human ovarian carcinoma cells. In: M. Nicolini (ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (Boston: Martinus Nijhoff), pp. 248-254.
4. +-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Research, 51, 3677-3681.
5. BAKKA, A., ENDRESEN, L., JOHNSEN, A. B. S., EDMINSON, P. D., and RUGSTAD, H. E., 1981, Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicology and Applied Pharmacology, 61, 215-226.
6. BARRY, M. A., BEHNKE, C. A., and EASTMAN, A. 1990, Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochemical Pharmacology, 40, 2353-2362.
7. BECK, D. J., POPOFF, S., SANCAR, A., and RUPP, W. D., 1985, Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II). Nucleic Acids Research, 13, 7395-7412.
8. BOHR, V. A., SMITH, C. A., OKUMOTO, D. S., and HANAWALT, P. C., 1985, DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell, 40, 359-369
9. BUBLEY, G. J., XU, J., KUPIEC, N., SANDERS, D., Foss, F., O'BRIEN, M., EMI, Y., TEICHER, B. A., and PATIERNO, S. R., 1996, Effect of DNA conformation on cisplatin adduct formation. Biochemical Pharmacology, 51, 717-721.
10. CALDECOTT, K., and JEGGO, P., 1991, Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents. Mutation Research DNA repair, 255, 111-121.
11. CHAO, C. C., HUANG, S. L., LEE, L. Y., and LIN-CHAO, S., 1991, Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum(II) Biochemical Journal, 277, 875-878.
12. CHEN, G., and ZELLER, W. J., 1992, Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines. Cancer Letters, 67, 27-33.
13. CHU, G., and CHANG, E., 1988, Xeroderma Pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science, 242, 564-567.
14. CHU, G., and CHANG, E., 1990, Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proceedings of the National Academy of Science, USA, 87, 3324-3327.
15. COLLINS, A. R., 1993, Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics. Mutation Research DNA repair, 293, 99-118.
16. COMIS, R. L., 1994, Cisplatin: the future. Seminars in Oncology, 21, 109-113.
17. DABHOLKAR, M., BOSTICK-BRUTON, F., WEBER, C., BOHR, V. A., EGWUAGU, C., and REED, E., 1992, ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. Journal of the National Cancer Institute, 84, 1512-1517.
18. DABHOLKAR, M., VIONNET, J., BOSTICK-BRUTON, F., YU, J. J., and REED, E., 1994, Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. Journal of Clinical Investigation, 94, 703-708.
19. DAHL, O., 1995, Interaction of heat and drugs in vitro and in vivo. In: M.H. Seegenschmiedt, P. Fessenden, and C. C. Vernon (eds), Thermoradiotherapy and thermochemotherapy. Volume 1: Biology, physiology and physics (Berlin Heidelberg, Germany: Springer-Verlag), pp. 103-121.
20. DEMPKE, W. C. M., SHELLARD, S. A., HOSKING, L. K., FICHTINGER-SCHEPMAN, A. M. J., and HILL, B. T., 1992, Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis, 13, 1209-1215.
21. EASTMAN, A., 1987, The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacological Therapeutics, 34, 155-166.
22. EASTMAN, A., and SCHULTE, N., 1988. Enhanced repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27, 4730-4734.
23. EICHHOLTZ-WIRTH, H., and HIETEL, B., 1990, Heat sensitization to cisplatin in two cell lines with different drug sensitivities. International Journal of Hyperthermia, 6, 47-55.
24. ENGELHARDT, R., 1987, Hyperthermia and drugs. Recent Results in Cancer Research, 104, 136-203.
25. FICHTINGER-SCHEPMAN, A. M. J., VAN DIJK-KNIJNENBURG, H. C. M., DIJT, F. J., VAN DER VELDE-VISSER, S. D., BERENDS, F., and BAAN, R. A., 1995, Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. Journal of Inorganic Biochemistry, 58, 177-191.
26. FISHER, G. H., and HAHN, G. M., 1982, Enhancement of cisplatinum(II)diamminedichloride cytotoxicity by hyperthermia. National Cancer Institute Monograms, 61, 255-257.
27. FRAVAL, H. N. A., and ROBERTS, J. J., 1979, Excision repair of cis-diamminedichloro-platinum(II)-induced damage to DNA of Chinese Hamster cells. Cancer Research, 39, 1793-1797.
28. 4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. Journal of National Cancer Institute, 86, 1781-1784.
29. GATELY, D. P., and HOWELL, S. B., 1993, Cellular accumulation of the anticancer agent cisplatin: A review. British Journal of Cancer, 67, 1171-1176.
30. GOTO, S., YOSHIDA, K., MORIKAWA, T., URATA., Y., SUZUKI, K., and KONDO, T., 1995, Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Research, 55, 4297-4301.
31. HAHN, G. M., 1982, Hyperthermia and Cancer (New York and London: Plenum Press).
32. HENLE, K. J., 1980, Sensitization to hyperthermia below 43 degrees C induced in Chinese hamster ovary cells by step-down heating. Journal of National Cancer Institute, 64, 1479-1483.
33. HERMAN, T. S., SWEETS, C. C., WHITE, D. M., and GERNER, E. W., 1982, Effect of heating rate on lethality due to hyperthermia and selected chemotherapeutic drugs. Journal of National Cancer Institute, 68, 487-491.
34. HERMAN, T. S., HENLE, K. J., NAGLE, W. A., Moss, A. J., and MONSON, T. T., 1984, Effect of step-won heating on the cytotoxicity of adriamycin, bleomycin, and cis-diamminedichloroplatinum. Cancer Research, 44, 1823-1826.
35. 2[tetrachloro-platinum(II)] in human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II) resistant subline. Cancer Research, 48, 5101-5105.
36. HERMAN, T. S. and TEICHER, B. A., 1994, Summary of studies adding systemic chemotherapy to local hyperthermia and radiation. International Journal of Hyperthermia, 10, 443-449.
37. HETTINGA, J. V. E., LEMSTRA, W., MEIJER, C., MULDER, N. H., KONINGS, A. W. T., DE VRIES, E. G. E., and KAMPINGA, H. H., 1994, Hyperthermic potentiation of cisplatin toxicity in a human small cell lung carcinoma cell line and a cisplatin resistant subline. International Journal of Hyperthermia, 10, 795-805.
38. HETTINGA, J. V. E., LEMSTRA, W., KONINGS, A. W. T., and KAMPINGA, H. H., 1995a, Cisplatin sensitivity and thermochemosensitization in thermotolerant cDDP-sensitive and -resistant cell lines. British Journal of Cancer, 71, 498-504.
39. HETTINGA, J. V. E., LEMSTRA, W., DE VRIES, E. G. E., KONINGS, A. W. T., and KAMPINGA, H. H., 1995b, Sensitization to cisplatin action by step-down heating in cDDP-sensitive and -resistant cells. International Journal of Cancer, 61, 722-726.
40. HETTINGA, J. V. E., 1996, Reduction of cisplatin resistance by hyperthermia (PhD Thesis, Univ. of Groningen, ISBN 90-367-0648-3) (PrintPartners Ipskamp bv, Enschede).
41. HETTINGA, J. V. E., LEMSTRA, W., MEIJER, C., DAM, W. A., UGES, D. R. A., KONINGS, A. W. T., DE VRIES, E. G. E., and KAMPINGA, H. H., 1997, Mechanism of hyperthermic potentiation of cisplatin action in cisplatin sensitive and -resistant tumor cells. British Journal of Cancer, 75, 1735-1743.
42. HILL, B. T., SCANLON, K. J., HANSSON, J., HARSTRICK, A., PERA, M., FICHTINGER-SCHEPMAN, A. M. J., and SHELLARD, S. A., 1994, Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Cancer, 30, 832-837.
43. HOEIJMAKERS, J. H. J., 1993, Nucleotide excision repair II: from yeast to mammals. Trends in Genetics, 9, 211-217.
44. HUANG, J. C., ZAMBLE, D. B., REARDON, J. T., LIPPARD, S. J., and SANCAR, A., 1994. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proceedings of the National Academy of Science USA, 91, 10394-10938.
45. ISHIDA, H., KIJIMA, H., OHTA, Y., KASHANI-SABET, M., and SCANLON, K. J., 1995, Mechanisms of cisplatin resistance and its reversal in human tumors. In: J. A. Kellen (ed), Mechanisms and reversal of multidrug resistance in cancer: the other alternatives (Boston, MA, USA: Birkhäuser).
46. ISHIKAWA, T., and ALI-OSMAN, F., 1993, Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Journal of Biological Chemistry, 268, 20116-20125.
47. ISHIKAWA, T., WRIGHT, C. D., and ISHIZUKA, H., 1994, GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. Journal of Biological Chemistry, 269, 29085-29093.
48. JONES, J. C., ZHEN, W., REED, E., PARKER, R. J., SANCAR, A., and BOHR, V. A., 1991, Genespecific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese Hamster Ovary cells. Journal of Biological Chemistry, 266, 7107-7107.
49. KAMPINGA, H. H., 1995, Effects of hyperthermia on chromatin organization: consequences for DNA repair and radiosensitivity. In: U. Hagen, H. Jung, and C. Streffer (eds), Congress Proceedings of the Tenth International Congress of Radiation Research Würzburg Germany, Vol. 2: Congress Lectures. Würzburg, Germany.
50. KELLAND, L. R., MISTRY, P., ABEL, G., FREIDLOS, F., LOH, S. Y., ROBERTS, J. J., and HARRAP, K. R., 1992, Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Research, 52, 1710-1716.
51. KELLEY, S. L., and ROZENCWEIG, M., 1989, Resistance to platinum compounds: mechanisms and beyond. European Journal of Cancer Clinical Oncology, 25, 1135-1140.
52. KELLEY, S. L., BASU, A., TEICHER, B. A., HACKER, M. P., HAMER, D. H., and LAZO, J. S., 1988, Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813-1815.
53. KONINGS, A. W. T., 1988, Membranes as targets for hyperthermic cell killing. Recent Results in Cancer Research, 109, 9-21.
54. KONINGS, A. W. T., HETTINGA, J. V. E., LEMSTRA, W., HUMPHREY, G. B., and KAMPINGA, H. H., 1993, Sensitizing for cis-diamminedicholoroplatinum(II) action by hyperthermia in resistant cells. International Journal of Hyperthermia, 9, 553-562.
55. LAI, G.-M., OZOLS, R. F., SMYTH, J. F., YOUNG, R. C., and HAMILTON, T. C., 1988, Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochemical Pharmacology, 37, 4597-4600.
56. LASZLO, A., 1992, The effects of hyperthermia on mammalian cell structure and function. Cell Proliferation, 25, 59-87.
57. LEOPOLD, K. A., OLESON, J. R., CLARKE-PEARSON, D., SOPER, J., BERCHUCK, A., SAMULSKI, T., PAGE, R. L., BLIVIN, J., TOMBERLIN, J. K., and DEWHIRST, M. W., 1993, Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. International Journal of Radiation Oncology, Biology and Physics, 27, 1245-1251.
58. LEHMANN, A. R., 1995, Nucleotide excision repair and the link with transcription. Trends in Biochemical Science, 237, 402-405.
59. 3H mammary carcinoma in vivo. Acta Oncologica, 31, 347-351.
60. Los, G., VAN VUGT, M. J. H., DEN, ENGELSE, L., and PINEDO, H. M., 1993, Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochemical Pharmacology, 46, 1229-1237.
61. MAJIMA, H., KASHIWADO, K., EGAWA, S., SUZUKI, N., and URANO, M., 1992, Interaction between the kinetics of thermotolerance and effect of cis-diamminedichloroplatinum(II) or bleomycin given at 37 or 43°C. International Journal of Hyperthermia, 8, 431-442.
62. MANSOURI, A., HENLE, K. J., BENSON, A. M., Moss, A. J., and NAGLE, W. A., 1989, Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drugresistance by hyperthermia. Cancer Research, 49, 2674-2678.
63. MAY, A., NAIRN, R. S., OKUMOTO, D. S., WASSERMAN, K., STEVNSNER, T., JONES, J. C., and BOHR, V. A., 1993, Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. Journal of Biological Chemistry, 268, 1650-1657.
64. MEIJER, C., MULDER, N. H., and DE VRIES, E. G. E., 1990, The role of detoxifying systems in resistance of tumor cells to cispiatin and adriamycin. Cancer Treatment Review, 17, 389-407.
65. MEIJER, C., MULDER, N. H., TIMMER-BOSSCHA, H., SLUITER, W. J., MEERSMA, G. J., and DE VRIES, E. G. E., 1992, Relationship of cellular glutathione to the cytotoxicity and the resistance of seven platinum compounds. Cancer Research, 52, 6885-6889.
66. MELLON, I., and HANAWALT, P. C., 1989, Induction of the Escherichia coli lactose operon selectively increases repair of its transcribed strand. Nature, 342, 95-98.
67. MEYN, R. E., CORRY, P. M., FLETCHER, S. E., and DEMETRIADES, M., 1980, Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Research, 40, 1136-1139.
68. OHNO, S., SIDDIK, Z. H., KIDO, Y., ZWELLING, L. A., and BULL, J. M. C., 1994, Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemotherapy and Pharmacology, 34, 302-306.
69. ORMEROD, M. G., O'NEILL, C., ROBERTSON, D., KELLAND, L. R., and HARRAP, K. R., 1996, Cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemotherapy and Pharmacology, 37, 463-471.
70. PAGE, J. D., HUSAIN, I., SANCAR, A., and CHANEY, S. G., 1990, Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair and lethality. Biochemistry, 29, 1016-1024.
71. PEREGO, P., GIAROLA, M., RIGHETTI, S. C., SUPINO, R., CASERINI, C., DELIA, D., PIEROTTI, M. A., MIYASHITA, T., REED, J. C., and ZUNINO, F., 1996, Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Research, 56, 556-562.
72. PLOOY, A. C. M., VAN DIJK, M., BERENDS, F., and LOHMAN, P. H. M., 1985, Formation and repair of DNA interstrand crosslinks in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Research, 45, 4178-4184.
73. RAMPINO, N. J., and BOHR, V. A., 1994, Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus compromising the divergent upstream gene and dihydrofolate reductase gene during early GI phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymerase. Proceedings of the National Academy of Science, USA, 91, 10977-10981.
74. RIETBROEK, R. C., BAKKER, P. J. M., SCHILTHUIS, M. S., POSTMA, A. J., ZUM VÖRDE SIVE VORDING, P. J., GONZALEZ GONZALEZ, D., KURTH, K.-H., BAKKER, A. J., and VEENHOF, C. H. N., 1996, Feasibility, toxicity, and preliminary results of weekly locoregional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer. International Journal of Radiation Biology and Physics, 34, 887-893.
75. SAKKERS, R. J., FILON, A. R., BRUNSTING, J. F., KAMPINGA, H. H., MULLENDERS, L. H. F., and KONINGS, A. W. T., 1993, Heat-shock treatment selectively affects induction and repair of cyclobutane pyrimidine dimers in transcriptionally active genes in ultravioletirradiated human fibroblasts. Radiation Research, 135, 343-350.
76. SAKKERS, R. J., FILON, A. R., KAMPINGA, H. H., KONINGS, A. W. T., and MULLENDERS, L. H., 1995a, Repair of UV-induced pyrimidine(6-4)pyrimidone photoproducts is selectively inhibited in transcriptionally active genes after heat treatment of human fibroblasts. International Journal of Radiation Biology, 67, 495-499.
77. SAKKERS, R. J., FILON, A. R., BRUNSTING, J. F., KAMPINGA, H. H., KONINGS, A. W. T., and MULLENDERS, L. H., 1995b, Selective inhibition of repair of active genes by hyperthermia is due to inhibition of global and transcription coupled repair pathways. Carcinogenesis, 16, 743-748.
78. SCANLON, K. J., KASHANI-SABET, M., MIYACHI, H., SOWERS, L. C., and ROSSI, J., 1989, Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Research, 9, 1301-1312.
79. SCHILDER, R. J., HALL, L., MONKS, A., HANDEL, L. M., FORNACE, A. J., OZOLS, R. F., FOJO, A. T., and HAMILTON, T. C., 1990, Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. International Journal of Cancer, 45, 416-422.
80. SCHMIDT, W. J., and CHANEY, S. G., 1993, Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Research, 53, 799-805.
81. SHIVJI, M. K. K., KENNY, M. K., and WOOD, R. D., 1992, Proliferating cell nuclear antigen is required for DNA excision repair. Cell, 69, 367-374.
82. 2 phase and cell death induced by cisplatin. Journal of the National Institute of Cancer Institute, 82, 749-755.
83. TAKAHASHI, I., MAEHARA, Y., KUSUMOTO, H., KOHNOE, S., and SUGIMACHI, K., 1993, Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1 -cyclobutane-dicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro. Cancer Chemotherapy and Pharmacology, 33, 31-35.
84. TAVERNA, P., HANSSON, J., SCANLON, K. J., and HILL, B. T., 1994, Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis, 15, 2053-5056.
85. TEBBS, R. S., ZHAO, Y., TUCKER, J. D., SCHEERER, J. B., SICILIANO, M. J., HWANG, M., LIU, N., LEGERSKI, R. J., and THOMPSON, L. H., 1995, Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proceedings of National Academy of Science, USA, 92, 6354-6358.
86. TEICHER, B. A., and HERMAN, T. S., 1994, Antitumor chemotherapy with hyperthermia and radiation trimodality therapy. In: M. Urano and E. Douple (eds), Hyperthermia and Oncology, vol. 4: Chemopotentiation by hyperthermia (Utrecht, The Netherlands: VSP), pp. 115-168.
87. TIMMER-BOSSCHA, H., MULDER, N. H., and DE VRIES, E. G. E., 1992, Modulation of cisdiamminedichloroplatinum(II) resistance: a review. British Journal of Cancer, 66, 227-238.
88. URANO, M., KAHN, J., and KENTON, L. A., 1990, The effect of cisdiamminedichloro-platinum(II) treatment at elevated temperatures on murine fibrosarcoma, FSa-II. International Journal of Hyperthermia, 6, 563-570.
89. VENEMA, J., VAN HOFFEN, A., NATARAJAN, A. T., VAN ZEELAND, A. A., and MULLENDERS, L. H. F., 1990, The residual repair capacity of xeroderma pigmentosum complementation group C fibroblasts is highly specific for transcriptionally active DNA. Nuclear Acids Research, 18, 443-448.
90. WALLNER, K. E., DEGREGORIO, M. W., and Li, G. C., 1986, Hyperthemic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese Hamster Ovary cells resistant to the drug. Cancer Research, 46, 6242-6245.
91. WOSIKOWSKI, K., REGIS, J. T., ROBEY, R. W., ALVAREZ, M., BUTERS, J. T. M., GUDAS, J. M., and BATES, S. E., 1995, Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth and Differentiation, 6, 1395-1403.
92. YAMAZAKI, H., SCHNEIDER, E., MYERS, C. E., and SINHA, B. K., 1994, Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochimica et Biophysica Acta, 1226, 89-96.
93. YANO, T., NAKATANI, K., WATANABE, A., NAKANO, H., and OHNISHI, T., 1993, Effects of preheating on cis-diamminedichtoroplatinum(II)-hyperthermia-induced tumour growth depression of transplantable human oesophageal cancer to nude mice. International Journal of Hyperthermia, 9, 699-708.
94. YAO, K.-S., GODWIN, A. K., JOHNSON, S. W., OZOLS, R. F., O'DWYER, P. J., and HAMILTON, T. C., 1995, Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Research, 55, 4367-4374.